Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma

References

• Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, et al. Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: Review of evidence. Curr Pharm Des 2012;18:3793–803
   PubMed Web of Science ®Google Scholar
• Cotte E, Passot G, Gilly FN, Glehen O. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2010;2:31–5
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43
   PubMed Web of Science ®Google Scholar
• Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460–65
   PubMed Web of Science ®Google Scholar
• Jones E, Alvarez Secord A, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, et al. Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 2006;22:161–72
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Sasaki H, Kurokawa T, Kawahara K, Shukunami K, Katayama K, et al. Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: A long-term follow-up. Oncol Rep 2005;13:121–5
   PubMedGoogle Scholar
• Salle B, Gilly FN, Carry PY, Sayag A, Brachet A, Braillon G. Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data. J Gynecol Obstet Biol Reprod 1993;22:369–71
   PubMedGoogle Scholar
• Arjona-Sanchez A, Muñoz-Casares C, Ortega-Salas R, Casado-Adam A, Sanchez-Hidalgo JM, Rufián-Peña S. Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 2014;30:408–11
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Shrager B, Jibara G, Yang MJ, Romanoff A, Hiotis S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: Outcomes from a single tertiary institution. J Gastrointest Surg 2014;18:1024–31
   PubMed Web of Science ®Google Scholar
• Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 2009;14:683–94
   PubMed Web of Science ®Google Scholar
• Gori J1, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005;15:233–9
   PubMed Web of Science ®Google Scholar
• Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, et al. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: Interim analysis of a phase II study. Ann Surg Oncol 2009;16:993–1000
   PubMed Web of Science ®Google Scholar
• Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. Gynecol Oncol 2011;122:215–20
   PubMed Web of Science ®Google Scholar
• Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235–41
   PubMed Web of Science ®Google Scholar
• Lentz SS, Miller BE, Kucera GL, Levine EA. Intraperitoneal hyperthermic chemotherapy using carboplatin: A phase I analysis in ovarian carcinoma. Gynecol Oncol 2007;106:207–10
   PubMed Web of Science ®Google Scholar
• Rufián S, Muñoz-Casares FC, Briceño J, Díaz CJ, Rubio MJ, Ortega R, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 2006;94:316–24
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Marples M, Nelstrop AE. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054–7
   PubMed Web of Science ®Google Scholar
• Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278–87
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events (version 4.03). Washington (DC): National Institutes of Health, 2010
   Google Scholar
• Rettenmaier MA, Abaid LN, Erwin MR, John CR, Micha JP, Brown JV, et al. A retrospective review of the GelPort system in single-port access pelvic surgery. J Minim Invasive Gynecol 2009;16:743–7
   PubMedGoogle Scholar
• Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194–200
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1–6
   PubMed Web of Science ®Google Scholar
• Konstantinidis IT, Young C, Tsikitis VL, Lee E, Jie T, Ong ES. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience. World J Gastrointest Surg 2012;4:135–40
   PubMedGoogle Scholar
• Brown JV, Micha JP, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH. A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer 2010;20:1132–6
   PubMedGoogle Scholar
• Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009;114:195–8
   PubMed Web of Science ®Google Scholar
• Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2012;22:778–85
   PubMed Web of Science ®Google Scholar
• Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435–43
   PubMed Web of Science ®Google Scholar
• Jenkins V, Catt S, Banerjee S, Gourley C, Montes A, Solis-Trapala I, et al. Patients’ and oncologists’ views on the treatment and care of advanced ovarian cancer in the UK: Results from the ADVOCATE study. Br J Cancer 2013;108:2264–71
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin – A Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 2005;99:591–6
   PubMed Web of Science ®Google Scholar